MAGE-A1 peptides presented by HLA class II molecules

US7157091B1 · kind B1 · utility

Assignee

• LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

• Jacques Van Snick · Brussels, BE
• Bernard Lethe · Brussels, BE
• Pascal Chaux · Brussels, BE
• Thierry Boon-Falleur · Brussels, BE
• Pierre van der Bruggen · Brussels, BE

Key dates

• Filing date: Jun 18, 1999
• Grant date: Jan 2, 2007
• Expiry date: Jun 18, 2019

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S530/828
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides isolated HLA DRB1*15-binding peptides consisting of the amino acid sequence set forth as SEQ ID NO:7 with 0–10 amino acids added to either or both ends of the amino acid sequence set forth as SEQ ID NO:7, and an endosomal targeting signal comprising an endosomal targeting portion of human invariant chain Ii or LAMP-1.